APA (7th ed.) Citation

Schneeweiss, A., Ettl, J., Lüftner, D., Beckmann, M. W., Belleville, E., Fasching, P. A., . . . Brucker, S. Y. (2020). Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer: Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. The breast, 54, . https://doi.org/10.1016/j.breast.2020.08.011

Chicago Style (17th ed.) Citation

Schneeweiss, Andreas, et al. "Initial Experience with CDK4/6 Inhibitor-based Therapies Compared to Antihormone Monotherapies in Routine Clinical Use in Patients with Hormone Receptor Positive, HER2 Negative Breast Cancer: Data from the PRAEGNANT Research Network for the First 2 Years of Drug Availability in Germany." The Breast 54 (2020). https://doi.org/10.1016/j.breast.2020.08.011.

MLA (9th ed.) Citation

Schneeweiss, Andreas, et al. "Initial Experience with CDK4/6 Inhibitor-based Therapies Compared to Antihormone Monotherapies in Routine Clinical Use in Patients with Hormone Receptor Positive, HER2 Negative Breast Cancer: Data from the PRAEGNANT Research Network for the First 2 Years of Drug Availability in Germany." The Breast, vol. 54, 2020, https://doi.org/10.1016/j.breast.2020.08.011.